A Comprehensive Third-generation Intervention for People With Psychosis and Post-traumatic Stress Symptoms
Launched by UNIVERSIDAD COMPLUTENSE DE MADRID · Nov 10, 2022
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is a randomized clinical trial at psychiatric rehabilitation services of the Public Network of Care for people with serious mental disorders. We hypothesize that participants receiving the intervention, in comparison with controls, will show a reduction in general, PTSD and psychotic symptomatology, an improvement in levels of functioning and well-being, a greater ability to regulate emotions with more help-seeking behaviours.
Given the complexity of both psychosis and PTSD and the reluctance of professionals to treat it, we plan to develop a precise comprehensive protocol. In o...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Those showing a high risk of PTSD (TSQ ≥6) will be further evaluated to determine whether they meet the inclusion criteria. Participants must:
- • Be between the ages of 18 and 65 fluent enough in Spanish language;
- • Meet the criteria for a diagnosis of a psychotic spectrum disorder or a mood disorder with psychotic symptoms according to MINI (Sheeman et al., 1997);
- • Meet PTSD diagnostic criteria according to the Clinician-Administered PTSD Scale (CAPS; Blake et al., 1995)
- Exclusion Criteria:
- • Those who have a diagnosis of substance or alcohol abuse or dependence in the 30 days prior to participation in the study
- • To have a severe neurocognitive problems or brain damage that interfere with the basic processing of information in psychotherapy.
About Universidad Complutense De Madrid
The Universidad Complutense de Madrid (UCM) is a prestigious academic institution renowned for its commitment to research and innovation in various fields, including health sciences. As a prominent sponsor of clinical trials, UCM leverages its extensive resources and expertise to advance medical knowledge and improve patient outcomes. The university fosters collaboration among researchers, clinicians, and industry partners, ensuring the highest standards of ethics and scientific rigor in its clinical research initiatives. UCM's dedication to education and research excellence positions it as a leader in the development of new therapeutic interventions and health solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pozuelo De Alarcón, Madrid, Spain
Patients applied
Trial Officials
Carmen Valiente, Ph.D.
Principal Investigator
Universidad Complutense de Madrid
Regina Espinosa, Ph.D.
Principal Investigator
Universidad Camilo Jose Cela
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials